generic times product news

Pharmacy Times, Volume 0, 0

Bethanechol Chloride Tablets, USP

Marketed by:IMPAX Laboratories Inc (Hayward, Calif)

Compared to:Urecholine Tablets (Odyssey Pharmaceuticals Inc)

Indication:November 3, 2006—IMPAX Laboratories announcedthat it received FDA approval for its bethanechol chloridetablets, USP, 5, 10, 25, and 50 mg. These tabletsare indicated for the treatment of acute postoperativeand postpartum nonobstructive (functional) urinaryretention and for neurogenic atony of the urinarybladder with retention.

Dosage Form:Tablets: 5, 10, 25, and 50 mg

For More Information:www.impaxlabs.com

Doxycycline Tablets

Marketed by:Mylan Pharmaceuticals Inc(Pittsburgh, Pa), a subsidiary ofMylan Laboratories Inc

Compared to:Adoxa Tablets(Par Pharmaceuticals)

Indication:November 8, 2006—Mylan Laboratories Incannounced that it received FDA approval for its abbreviatednew drug application for doxycycline tablets,50, 75, and 100 mg. These tablets have beenapproved for the treatment of a wide range of infections.To reduce the development of drug-resistantbacteria and maintain the effectiveness of doxycyclinetablets and other antibacterial drugs, doxycyclinetablets should be used only to treat or prevent infectionsthat are proven or strongly suspected to becaused by susceptible bacteria.

Dosage Form:Tablets: 50, 75, and 100 mg

For More Information:www.mylan.com

Moexipril HCl Tablets

Marketed by:Paddock Laboratories Inc(Minneapolis, Minn)

Compared to:Univasc (Warner LambertCo LLC)

Indication:November 30, 2006—Paddock Laboratoriesannounced the availability of Moexipril HCl tablets.These tablets, which are AB-rated, are indicated fortreatment of patients with hypertension. They may beused alone or in combination with thiazide diuretics.

Dosage Form:Tablets: 7.5 and 15 mg

For More Information:www.paddocklabs.com

Oxybutynin Chloride Extended-release Tablets

Marketed by:Teva Pharmaceuticals(North Wales, Pa)

Compared to:Ditropan XL (Alza Corp)

Indication:November 10, 2006—TevaPharmaceuticals announced theintroduction of Oxybutynin Chloride Extended-releaseTablets. Oxybutynin chloride, which is AB-rated, is anantispasmodic, anticholinergic agent indicated for thetreatment of overactive bladder with symptoms ofurge urinary incontinence, urgency, and frequency.

Dosage Form:Tablets: 15 mg

For More Information:www.tevausa.com888-TEVA USA (888-838-2872)

Pravastatin Tablets 10, 20, and 40 mg

Marketed by:Barr Pharmaceuticals Inc and itssubsidiary, Pliva d.d.(Woodcliff Lake, NJ)

Compared to:Pravachol (Bristol-Myers Squibb)

Indication:November 28, 2006—Pliva, a subsidiary of BarrPharmaceuticals Inc, received FDA approval for itsabbreviated new drug application to manufacture andmarket Pravastatin tablets, 10, 20, and 40 mg.Pravastatin is indicated for the primary prevention ofcoronary events in hypercholesterolemic patientswithout clinically evident coronary heart disease, andsecondary prevention of cardiovascular events inpatients with clinically evident coronary heart disease.

Dosage Form:Tablets: 10, 20, and 40 mg

For More Information:www.barrlabs.com